Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

404 ARTÍCULOS , VIENDO DEL 241 AL 255

The Potential of Neurofilament Light as a Biomarker in Alzheimer's Disease

Xiong YL, Meng T, Luo J, Zhang H.

Eur Neurol. 2021;84(1):6-15. doi: 10.1159/000513008. Epub 2021 Jan 21.

Advances in Brain Amyloid Imaging

Krishnadas N, Villemagne VL, Doré V, Rowe CC.

Semin Nucl Med. 2021 May;51(3):241-252. doi: 10.1053/j.semnuclmed.2020.12.005. Epub 2021 Jan 19.

Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer's disease

Zhang Y, Wang Y, Shi C, Shen M, Lu F.

Transl Neurodegener. 2021 Feb 1;10(1):6. doi: 10.1186/s40035-021-00230-9.

New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease

Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, Maccioni RB.

J Alzheimers Dis. 2021;82(s1):S51-S63. doi: 10.3233/JAD-201059.

Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases

Campese N, Palermo G, Del Gamba C, Beatino MF, Galgani A, Belli E, Del Prete E, Della Vecchia A, Vergallo A, Siciliano G, Ceravolo R, Hampel H, Baldacci F.

Expert Rev Proteomics. 2021 Jan;18(1):27-48. doi: 10.1080/14789450.2021.1886929. Epub 2021 Mar 7.

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework

Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, Nordberg A, Frisoni GB, Garibotto V, Ossenkoppele R.

Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2097-2109. doi: 10.1007/s00259-020-05118-w. Epub 2021 Feb 6.

Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects

Rostamzadeh A, Schwegler C, Gil-Navarro S, Rosende-Roca M, Romotzky V, Ortega G, Canabate P, Moreno M, Schmitz-Luhn B, Boada M, Jessen F, Woopen C.

J Alzheimers Dis. 2021;80(2):601-617. doi: 10.3233/JAD-200484.

The Contribution of Ocular Biomarkers in the Differential Diagnosis of Alzheimer's Disease versus Other Types of Dementia and Future Prospects

Chalkias E, Topouzis F, Tegos T, Tsolaki M.

J Alzheimers Dis. 2021;80(2):493-504. doi: 10.3233/JAD-201516.

What have we learned from cognition in the oldest-old

Kawas CH, Legdeur N, Corrada MM.

Curr Opin Neurol. 2021 Apr 1;34(2):258-265. doi: 10.1097/WCO.0000000000000910.

Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Kokkinou M, Beishon LC, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, Hayen A, Desai M, Ashok AH, Paul EJ, Georgopoulou A, Casoli T, Quinn TJ, Ritchie CW.

Cochrane Database Syst Rev. 2021 Feb 10;2(2):CD010945. doi: 10.1002/14651858.CD010945.pub2.

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, Hansson O, Nordberg A, Ossenkoppele R, Sabri O, Giovanni BFG, Garibotto V, Drzezga A.

Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2110-2120. doi: 10.1007/s00259-020-05156-4. Epub 2021 Feb 16.

Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics

Zetterberg H, Blennow K.

Mol Neurodegener. 2021 Feb 19;16(1):10. doi: 10.1186/s13024-021-00430-x.

New insights into atypical Alzheimer's disease in the era of biomarkers

Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME.

Lancet Neurol. 2021 Mar;20(3):222-234. doi: 10.1016/S1474-4422(20)30440-3.

Melatonin levels in the Alzheimer's disease continuum: a systematic review

Nous A, Engelborghs S, Smolders I.

Alzheimers Res Ther. 2021 Feb 23;13(1):52. doi: 10.1186/s13195-021-00788-6.

Empirical assessment of biases in cerebrospinal fluid biomarkers of Alzheimer's disease: an umbrella review and re-analysis of data from meta-analyses

Jeong DY, Lee J, Kim JY, Lee KH, Li H, Lee JY, Jeong GH, Yoon S, Park EL, Hong SH, Kang JW, Song TJ, Leyhe T, Eisenhut M, Kronbichler A, Smith L, Solmi M, Stubbs B, Koyanagi A, Jacob L, Stickley A, Thompson T, Dragioti E, Oh H, Brunoni AR, Carvalho AF, Kim MS, Yon DK, Lee SW, Yang JM, Ghayda RA, Shin JI, Fusar-Poli P.

Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1536-1547. doi: 10.26355/eurrev_202102_24862.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias